Robert Osborne


Authored Items

Older Patients with AML Live Longer with Azacitidine

August 2014, Vol 5, No 6 - EHA 2014

Milan, Italy—Older patients with acute myeloid leukemia (AML) gained a “clinically significant,” if not statistically significant improvement in survival when treated with azacitidine (Vidaza) rather than with conventional therapy, reported Hervé Dombret, MD, hematologist, Hôpital Saint Louis in Paris, France, at the European Hematology Association meeting. [ Read More ]

Stopping TKIs Safe after Deep Molecular Response

August 2014, Vol 5, No 6 - EHA 2014

Milan, Italy—More than 60% of patients with chronic myeloid leukemia (CML) were free of relapse 6 months after stopping tyrosine kinase inhibitor (TKI) therapy that led to deep molecular remission, according to the interim results from an ongoing trial reported by Susanne Saussele, MD, of Universitätsmedizin Mannheim, Germany, at the 2014 European Hematology Association meeting. [ Read More ]